Showing 1 - 10 of 272
Persistent link: https://www.econbiz.de/10011393507
Compared with developed economies, health expenditure in China is not particularly high on a per capita basis or as a share of Gross Domestic Product (GDP). Similarly, pharmaceutical expenditure in comparative perspective is not particularly high on a per capita basis or as a percentage of GDP....
Persistent link: https://www.econbiz.de/10012247334
This paper examines the financing, pricing, and utilization of pharmaceuticals in China the pharmaceutical system as it …
Persistent link: https://www.econbiz.de/10012247481
India for traditional platforms and high-volume production. Countries with domestic COVID-19 vaccine manufacturing capacity …
Persistent link: https://www.econbiz.de/10014578934
challenge, with manufacturing mostly concentrated in the US and Europe for high-value mRNA vaccines, and China and India for …
Persistent link: https://www.econbiz.de/10014579804
Persistent link: https://www.econbiz.de/10010523369
Persistent link: https://www.econbiz.de/10010523456
This publication, which is based on the unique methodology and tools developed for the World Bank Institute/Harvard School of Public Health Flagship Course on Health System Reform and Sustainable Financing, provides a powerful set of resources to help policy makers better navigate the...
Persistent link: https://www.econbiz.de/10012550449
Persistent link: https://www.econbiz.de/10012245397